Ph 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept + Keytruda in Patients with Untreated HPV-Mediated Oropharyngeal Cancer initiated May 7, 2024
First Patients Dosed in Two Ph 1 Trials of REM-422 of Adenoid Cystic Carcinoma (ACC) and AML/MDS May 7, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC May 7, 2024
Positive Recommendation of IDMC Following Completion of Enrollment in REGAL Ph 3 Study Announced May 1, 2024
Ph 2 trial of VB10.16 with or without Tecentriq initiated for the treatment of HPV16+ve, PD-L1+ve, recurrent or metastatic cervical cancer May 1, 2024
First Cohort Completed and Second Cohort of Ph 1/2 Study of INKmune™ NK Cell Therapy in Patients with Metastatic CRPC Initiated May 1, 2024
Move-Forward Ph 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous NSCLC selected April 23, 2024
Successful Completion of Higher Dose Second Cohort in Ph 1/1b Trial of BP1002 in R/R AML Patients April 23, 2024
Clinical development of voruciclib to be advanced and new formulation of ME-344 to be enabled April 16, 2024
First Patient Dosed in First-in-Human Ph 1/2 Trial of BBI-825 in Patients with Resistance Gene Amplifications April 16, 2024
REJOICE-Ovarian01 Ph 2/3 Trial of Raludotatug Deruxtecan Initiated in Platinum-Resistant Ovarian Cancer April 9, 2024
Ph 3 Trial of MK-1084 + KEYTRUDA for 1L Treatment of Certain Patients With Metastatic NSCLC initiated April 9, 2024
Alliance A032103 (MODERN) Randomized, Ph 2/3 Adjuvant Trial in Urothelial Cancer announced April 9, 2024
Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL April 9, 2024